Target intelligence / Profile preview

Red blood cell deformability (RBC deformability)

Target
RBC deformability
Molecular classification
Other (cellular biomechanical property, not a molecule, receptor, or enzyme)
01

Overview

Red blood cell deformability is a biophysical property reflecting the ability of erythrocytes to change their shape in response to mechanical forces as they traverse the microcirculation, enabling passage through capillaries smaller than themselves and supporting efficient oxygen transport. This property is determined by the interplay of membrane flexibility, cytoskeletal structure, cytoplasmic viscosity, and hydration status. Loss of RBC deformability occurs in various diseases (including sickle cell disease, hemolytic anemias, diabetes, and neurodegenerative conditions), during blood storage, and with aging, leading to impaired circulation and tissue hypoxia. Several clinical and experimental strategies exist to measure and quantify this property, and its assessment is increasingly used as a biomarker for systemic disease, transfusion efficacy, well as biological aging.

Other names
Erythrocyte deformabilityred cell deformabilityRBC flexibility
02

Mechanism of action

Drugs affecting RBC deformability may improve cytoskeletal or membrane stability, shift cell hydration or oxidative state, or reduce hemoglobin polymerization (in sickle cell disease).

03

Biological functions

Microcirculatory flow (enables RBCs to pass through small capillaries)Oxygen delivery (critical for efficient tissue oxygenation)Blood rheology (influences whole blood viscosity and flow)ATP release during deformation (may help regulate local blood flow)
04

Disease associations

Hemolytic anemias (e.g., sickle cell disease, hereditary spherocytosis, thalassemias)Diabetes mellitus (reduced deformability correlates with disease state)Neurodegenerative diseases (potential diagnostic biomarker)Transfusion medicine (loss of deformability during storage)
05

Safety considerations

Transfusion of low-deformability RBCs: risk of capillary blockage, poor tissue perfusion, and increased morbidity, especially post-surgery or in critically ill patientsRBC storage lesion: progressive loss of deformability during blood bank storage
06

Interacting drugs

Hydroxyurea

1 more in the full profile.

07

Biomarkers

RBC elongation index/ektacytometry (clinical measurement)Microfluidic deformability metricsImaging-based morphology scores

Beyond the preview

Go deeper on Red blood cell deformability (RBC deformability).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Red blood cell deformability (RBC deformability).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call